Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Amolyt Pharma"},{"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma to Present New Phase 1 Data on AZP-3601 and Preclinical Data on AZP-3404 at Upcoming Scientific Conferences","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Amolyt Pharma"},{"company":"Adocia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Peptide","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Adocia"},{"company":"Amolyt Pharma","sponsor":"Sectoral Asset Management","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Amolyt Pharma"},{"company":"Inserm","sponsor":"T.H.A.C.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"T.H.A.C Announces the Acquisition of an International Patent on Its Drug Candidate ALF-5755 For the Early Treatment of Type 2 Diabetes Mellitus and Relative to the Gut Microbiota Composition","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Inserm"},{"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma Announces European Commission Has Granted Orphan Drug Designation to AZP-3601 for the Treatment of Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Amolyt Pharma"},{"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma Announces US IND Clearance for the Ongoing Clinical Trial of AZP-3601 in Patients with Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Amolyt Pharma"},{"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Amolyt Pharma"}]

Amolyt Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO

Details:

AZP-3601, a long-acting parathyroid hormone (PTH) analog, normalizes blood calcium in thyroparathyroidectomized (TPTX) rats without causing deleterious changes in bone.

Lead Product(s): AZP-3601

Therapeutic Area: Endocrinology Product Name: AZP-3601

Highest Development Status: Phase I Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 16, 2022

ASK
US

Upload
your Pipeline Activity

Amolyt Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Amolyt Pharma Announces US IND Clearance for the Ongoing Clinical Trial of AZP-3601 in Patients with Hypoparathyroidism

Details:

AZP-3601, investigational therapeutic peptide designed to target specific conformation of PTH receptor safely produce sustained and stable levels of calcium in blood and manage symptoms of hypoparathyroidism, with goal of consequently preventing chronic kidney disease.

Lead Product(s): AZP-3601

Therapeutic Area: Endocrinology Product Name: AZP-3601

Highest Development Status: Phase I Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 17, 2022

ASK
US

Upload
your Pipeline Activity

Amolyt Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Amolyt Pharma Announces European Commission Has Granted Orphan Drug Designation to AZP-3601 for the Treatment of Hypoparathyroidism

Details:

AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyroidism.

Lead Product(s): AZP-3601

Therapeutic Area: Endocrinology Product Name: AZP-3601

Highest Development Status: Phase I Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 01, 2022

ASK
US

Upload
your Pipeline Activity

Inserm

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

T.H.A.C Announces the Acquisition of an International Patent on Its Drug Candidate ALF-5755 For the Early Treatment of Type 2 Diabetes Mellitus and Relative to the Gut Micr...

Details:

This acquisition strengthens the protection and the potential of the First in Class drug candidate of T.H.A.C which incorporates the active ingredient ALF-5755 for the treatment of Type 2 Diabetes Mellitus and severe complications.

Lead Product(s): ALF-5755

Therapeutic Area: Endocrinology Product Name: ALF-5755

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: T.H.A.C.

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition September 27, 2021

ASK
US

Upload
your Pipeline Activity

Amolyt Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners

Details:

Amolyt will use the proceeds to advance its pipeline for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404.

Lead Product(s): AZP-3601

Therapeutic Area: Endocrinology Product Name: AZP-3601

Highest Development Status: Phase I Product Type: Peptide

Partner/Sponsor/Collaborator: Sectoral Asset Management

Deal Size: $80.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing September 16, 2021

ASK
US

Upload
your Pipeline Activity

Adocia

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes

Details:

Pramlintide, despite being the only drug approved as an adjunct to insulin in type 1 diabetes, is underused as it requires three additional daily injections in addition to the multiple injections of insulin.

Lead Product(s): Insulin Lispro,Pramlintide

Therapeutic Area: Endocrinology Product Name: BC LisPram

Highest Development Status: Phase I Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 29, 2021

ASK
US

Upload
your Pipeline Activity

Amolyt Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Amolyt Pharma to Present New Phase 1 Data on AZP-3601 and Preclinical Data on AZP-3404 at Upcoming Scientific Conferences

Details:

Data from all cohorts from its Phase 1 Single Ascending Dose clinical trial evaluating AZP-3601, a parathyroid hormone (PTH) analog specifically designed for the treatment of hypoparathyroidism will be presented.

Lead Product(s): AZP-3601

Therapeutic Area: Endocrinology Product Name: AZP-3601

Highest Development Status: Phase I Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2021

ASK
US

Upload
your Pipeline Activity

Amolyt Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism

Details:

AZP-3601 is a therapeutic peptide designed to target a specific configuration of the parathyroid hormone (PTH) receptor in order to safely produce sustained levels of calcium in the blood and thereby manage the symptoms of hypoparathyroidism.

Lead Product(s): AZP-3601

Therapeutic Area: Endocrinology Product Name: AZP-3601

Highest Development Status: Phase I Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 06, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY